Synapse - A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)

A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056) Meeting Abstract

Authors:	Kyi, C.; Rubinstein, M. M.; Shah, P.; Zhou, Q.; Iasonos, A.; Liu, Y.; Ramirez, L.; Paroder, V.; Green, A.; Friedman, C. F.; Grisham, R. N.; O'Cearbhaill, R. E.; Troso-Sandoval, T. A.; Cohen, S. M.; Lichtman, S. M.; Konner, J. A.; Hensley, M. L.; Zamarin, D.; Aghajanian, C.; Makker, V.
Abstract Title:	A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056)
Meeting Title:	2022 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	40
Issue:	16 Suppl.
Meeting Dates:	2022 Jun 3-7
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2022-06-01
Language:	English
ACCESSION:	WOS:000863680301646
PROVIDER:	wos
DOI:	10.1200/JCO.2022.40.16_suppl.5589
Notes:	Meeting Abstract: 5589 -- Meeting also held virtually -- Source: Wos